Leerink analyst Joseph Schwartz notes Outperform-rated Sarepta (SRPT) disclosed two-year Part 1 and one-year Part 2 data from the EMBARK study with Elevidys. The firm views these topline results favorably, though investor focus is likely to remain on the launch. While limited to topline data in the press release, Leerink views these results as an incremental positive for Elevidys’ ongoing launch, especially given the recent negative sentiment swirling around regarding gene therapy in Duchenne muscular dystrophy. The firm views its FY25 sales estimate of about $2.1B as achievable, especially following strong beats in Q3 and Q4.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta announces topline results from EMBARK study
- Sarepta’s Elevidys launch remains strong with solid beat, says JPMorgan
- Sarepta reports preliminary Q4 net product revenue $638.2M
- Sarepta price target lowered to $165 from $182 at RBC Capital
- 5 “Strong Buy” Healthcare Stocks to Buy Before They Soar in 2025